Cargando…
Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models
Hydroxychloroquine (HCQ) is a well-known anti-inflammatory drug but is also known as an anti-inflammatory drug. Here, we evaluate the influence of HCQ treatment on the effect of anti-PD1 tumor immunotherapy. Anti-PD1 therapy-sensitive tumor lines MC38, CT26, and RIL-175 were used to investigate the...
Autores principales: | Wabitsch, Simon, McVey, John C., Ma, Chi, Ruf, Benjamin, Kamenyeva, Olena, McCallen, Justin D., Diggs, Laurence P., Heinrich, Bernd, Greten, Tim F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807148/ https://www.ncbi.nlm.nih.gov/pubmed/33490900 http://dx.doi.org/10.1016/j.isci.2020.101990 |
Ejemplares similares
-
Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice
por: Wabitsch, Simon, et al.
Publicado: (2021) -
NAFLD indirectly impairs antigen-specific CD8(+) T cell immunity against liver cancer in mice
por: McVey, John C., et al.
Publicado: (2022) -
Evaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine production in vivo and in vitro
por: Wabitsch, Simon, et al.
Publicado: (2021) -
Subcutaneous Ligation
por: McVey, B. P.
Publicado: (1892) -
Can GPR4 Be a Potential Therapeutic Target for COVID-19?
por: Yang, Li V., et al.
Publicado: (2021)